Subtype
Malignant Hepatobiliary Neoplasm
CI-CAN-00001136Explore in graph →
1,160 active trials17 approved drugs42 evidence items
- NCIt
- C8609
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001136Explore in graph →
Clinical trials
5,029 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (561)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07115550 | A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma | not yet recruiting | N/A | 24 | Huai'an First People's HospitalOTHER | 0 | Aug 11, 2025 | clinicaltrials |
| NCT07100236 | 29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness | not yet recruiting | — | 350 | Junjie XuOTHER | 1 | Aug 3, 2025 |
| clinicaltrials |
| NCT07099794 | A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen | not yet recruiting | Phase 2 | 90 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07088133 | Clinical Trials of the Hepatitis B Sandwich Combination Therapy for Treating Patients Infected With Hepatitis B Virus | not yet recruiting | N/A | 12 | Shanghai Zhongshan HospitalOTHER | 0 | Jul 28, 2025 | clinicaltrials |
| NCT07077369 | WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy | not yet recruiting | Phase 1 | 10 | West China HospitalOTHER | 0 | Jul 22, 2025 | clinicaltrials |
| NCT07077798 | Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection | not yet recruiting | N/A | 234 | Wan-Guang ZhangOTHER | 0 | Jul 22, 2025 | clinicaltrials |
| NCT07078292 | The Efficacy and Safety of First-line Treatment Combined With Immunotherapy for Advanced Hepatocellular Carcinoma: a Single Center, Real-world Study | not yet recruiting | — | 400 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 22, 2025 | clinicaltrials |
| NCT07078305 | Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment | not yet recruiting | Phase 2 | 134 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 22, 2025 | clinicaltrials |
| NCT07075419 | JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure | not yet recruiting | Phase 1 / Phase 2 | 10 | West China HospitalOTHER | 0 | Jul 20, 2025 | clinicaltrials |
| NCT07064668 | Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study | not yet recruiting | Phase 2 | 300 | Tongji HospitalOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT07062328 | A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC(HP-BTC-002) | not yet recruiting | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 0 | Jul 14, 2025 | clinicaltrials |
| NCT07064447 | Spanish Registry of Direct Cholangiopancreatoscopy by Single Operator | not yet recruiting | — | 260 | Germans Trias i Pujol HospitalOTHER | 0 | Jul 14, 2025 | clinicaltrials |
| NCT07058649 | Downstaging Prediction Model for HCC | not yet recruiting | — | 369 | Beijing Tsinghua Chang Gung HospitalOTHER | 0 | Jul 10, 2025 | clinicaltrials |
| NCT07056270 | Development of a Set of Auxiliary Decision-making System for the Perioperative Period of Hepatectomy Based on Static CT and Artificial Intelligence. | not yet recruiting | — | 500 | Tongji HospitalOTHER | 0 | Jul 9, 2025 | clinicaltrials |
| NCT07055048 | The Diagnostic Efficacy and Lesion Detection Advantages of 18F-FDG PET/Contrast-enhanced MRI in Malignant Liver Lesions | not yet recruiting | — | 60 | Shanghai East HospitalOTHER | 0 | Jul 8, 2025 | clinicaltrials |
| NCT07045558 | HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC | not yet recruiting | — | 28 | RenJi HospitalOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06780553 | Validation of the Proteomic Profiling as a Diagnostic Test for Extra-hepatic Cholangiocarcinoma(PROFI-CHOL) | not yet recruiting | — | 60 | University Hospital, BordeauxOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT06194461 | LTFU for All Cell and Gene Therapy Studies(LOCUS) | not yet recruiting | — | 64 | AstraZenecaINDUSTRY | 4 | Jun 27, 2025 | clinicaltrials |
| NCT07038863 | Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France(Mondelta) | not yet recruiting | N/A | 2,000 | Hospices Civils de LyonOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07036185 | A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors | not yet recruiting | Phase 1 | 66 | Shanghai Bao Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07010588 | Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk(SHORT) | not yet recruiting | N/A | 1,389 | Peking University People's HospitalOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT07003815 | Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer | not yet recruiting | Phase 2 | 62 | Tongji HospitalOTHER | 0 | Jun 4, 2025 | clinicaltrials |
| NCT06999512 | Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer(HPB70+) | not yet recruiting | Phase 2 / Phase 3 | 526 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06994572 | Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 1 | 141 | Captor Therapeutics S.A.INDUSTRY | 0 | May 29, 2025 | clinicaltrials |
| NCT06993025 | Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT06990620 | TACE Plus Ivonescimab for Unresectable Non-Metastatic HCC(TACE HCC) | not yet recruiting | Phase 1 | 56 | Fudan UniversityOTHER | 0 | May 25, 2025 | clinicaltrials |
| NCT06984718 | A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC | not yet recruiting | Phase 2 | 120 | AkesoINDUSTRY | 0 | May 22, 2025 | clinicaltrials |
| NCT05660213 | A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer | not yet recruiting | — | 750 | Fudan UniversityOTHER | 0 | May 20, 2025 | clinicaltrials |
| NCT06977399 | The Application Value of Spectral CT in the Accurate Staging of Liver Cancer | not yet recruiting | N/A | 150 | Yunnan Cancer HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT06971237 | SIRT and Peri-immunotherapy : a New Concept(IMSIRT) | not yet recruiting | — | 60 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06958484 | Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence | not yet recruiting | Phase 2 | 60 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 0 | May 6, 2025 | clinicaltrials |
| NCT06946849 | Second-line Regimen Combined With Radiotherapy Versus Without Radiotherapy in Patients With Locally Advanced/Oligometastatic ICC After Failure of First-line Treatment：an Open-label, Randomized, Controlled Phase II Clinical Study(SED-RO-ICC) | not yet recruiting | Phase 2 | 76 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06938451 | Relationship Between FGF19 Overexpression and Disease Prognosis(FGF19) | not yet recruiting | — | 100 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06935175 | A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer | not yet recruiting | Phase 2 | 53 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT06903663 | The Epidemiology of Patients Treated With ATZ+BEV in Real Life Setting(MANIFEST-HCC) | not yet recruiting | — | 100 | Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian FodorOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT06928415 | Efficacy and Safety of Liver Transplantation for Hepatocellular Carcinoma With Bile Duct Tumor Thrombus: a Single-arm, Multicenter, Prospective Study (HCC-BDTT in LT) | not yet recruiting | — | 130 | Zhejiang UniversityOTHER | 0 | Apr 15, 2025 | clinicaltrials |
| NCT06923176 | Effect of Biejia-Ruangan Compound on Survival Rate and Recurrence Rate of Hepatocellular Carcinoma After Radical Treatment(BRCSRRRHCCART) | not yet recruiting | Phase 4 | 704 | Zhiyun YangOTHER | 0 | Apr 11, 2025 | clinicaltrials |
| NCT06919848 | Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06) | not yet recruiting | Phase 2 | 74 | Fudan UniversityOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06911086 | SH-LPS System in Preoperative Planning for Liver Resection | not yet recruiting | Phase 2 / Phase 3 | 100 | Zhejiang Cancer HospitalOTHER | 0 | Apr 4, 2025 | clinicaltrials |
| NCT06903273 | Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma(TisGCS for BTC) | not yet recruiting | Phase 2 | 35 | National Cheng-Kung University HospitalOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06900478 | Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC | not yet recruiting | Phase 2 | 25 | Hua LiOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT06896396 | Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 60 | Zhiyong HuangOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06894524 | Retrospective Clinical Validation of HepatoPredict | not yet recruiting | — | 200 | OphiomicsINDUSTRY | 0 | Mar 25, 2025 | clinicaltrials |
| NCT06884982 | An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with Lenvatinib | not yet recruiting | Phase 2 | 30 | Northern Jiangsu People's HospitalOTHER | 0 | Mar 19, 2025 | clinicaltrials |
| NCT06871930 | Characteristic and Survival Outcomes in Hepatocellular Carcinoma Patients: on Top of Viral Hepatitis Versus Combined Viral and Metabolic-Associated Steatotic Liver Disease | not yet recruiting | — | 150 | Assiut UniversityOTHER | 0 | Mar 12, 2025 | clinicaltrials |
| NCT05195294 | Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC | not yet recruiting | Phase 2 | 55 | Lion TCR Pte. Ltd.INDUSTRY | 0 | Mar 10, 2025 | clinicaltrials |
| NCT06867432 | Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 10, 2025 | clinicaltrials |
| NCT06841185 | A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma | not yet recruiting | Phase 3 | 656 | Shanghai Henlius BiotechINDUSTRY | 0 | Feb 24, 2025 | clinicaltrials |
| NCT06836518 | Sialic Acid in Hepatocellular Carcinoma | not yet recruiting | — | 100 | Sohag UniversityOTHER | 0 | Feb 20, 2025 | clinicaltrials |
| NCT06836778 | Comparative Study of Carvedilol Monotherapy Versus Combination Therapy With Endoscopic Variceal Ligation (EVL) for Primary Prophylaxis of Variceal Bleeding in Patients With Hepatocellular Carcinoma With High-Risk Esophageal Varices | not yet recruiting | N/A | 100 | Institute of Liver and Biliary Sciences, IndiaOTHER | 1 | Feb 20, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 11, 2025source: clinicaltrials